Table 2

Key studies of TNF-blocker therapy in psoriatic arthritis

Outcomes reported


Dactylitis

Function

Therapy

Published study

Primary outcome

Radiologic outcomes

Joint

Skin

Nail

Enthesitis

QoL

Pain

EMS

Fatigue

CRP/ ESR


Infliximab

Antoni and colleagues [59], Kavanaugh and colleagues [52]

ACR20 at week 16

mvdH-SS at week 50

x

x

x

x

x

x

x

Infliximab

Antoni and colleagues [60], van der Heijde and colleagues [56]

ACR20 at week 14

mvdH-SS at weeks 24 and 54

x

x

x

x

x

x

x

x

Etanercept

Mease and colleagues [61]

PsARC at week 12

NA

x

x

x

x

x

Etanercept

Mease and colleagues [58]

ACR20 at week 12

mTSS at months 6 and 12

x

x

x

x

x

Adalimumab

Mease and colleagues [54]

ACR20 at week 12

mTSS at week 24

x

x

x

x

x

x

x

Golimumab

Kavanaugh and colleagues [62]

ACR20 at week 14

NA

x

x

x

x

x

x


ACR20, American College of Rheumatology 20% improvement; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate, EMS, early morning stiffness; mvdH-SS, modified van der Heijde–Sharp score; mTSS, modified total Sharp score; NA, not available; PsARC, Psoriasis Arthritis Response Criteria; QoL, quality of life.

Schett et al. Arthritis Research & Therapy 2011 13(Suppl 1):S4   doi:10.1186/1478-6354-13-S1-S4